Qubiotech Health Intelligence Is an innovative company that develops its own technology, and is open to the incorporation of external technology through research transfer contracts.
Our interests are focused on the development of cloud image quantification applications to help diagnose Neurodegenerative diseases. We start from developments with a solid clinical base so that its translation into medical practice is as fast, safe and effective as possible.
We are currently working on the following developments:
Patients with mild cognitive impairment who have an abnormally reduced volume of the hippocampus have been shown to be 4 times more likely to develop Alzheimer's disease in the future than those with a normal hippocampus. The quantification of atrophies of different brain regions (temporal means, hippocampus) or the whole brain are currently considered as valid biomarkers related to diseases that cause cognitive impairment.
Qubiotech Is developing a new application of Neurocloud based on quantification technology that will allow the quantitative measurement of atrophies. Launch in 2018.
Giovanni B. Frisoni, Nick C. Fox, Clifford R. Jack, Philip Scheltens & Paul M. Thompson (2010). The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology 6, 67-77
Atiya, Monika ; Hyman, Bradley T. , ; Albert, Marilyn S. ; Killiany, Ronald (2003). Structural Magnetic Resonance Imaging in Established and Prodromal Alzheimer Disease: A Review. Alzheimer Disease & Associated Disorders.- Volume 17 - Issue 3 - pp 177-195
Fox, Nick C et al. (2004). Imaging cerebral atrophy: normal ageing to Alzheimer's disease. The Lancet , Volume 363 , Issue 9406 , 392 - 394
QUBIOLEARN is a cloud based tool to train the diagnosis of neurological diseases from PET images.
The radiopharmaceuticals of SPECT HMPAO 99mTc and ECD 99mTc easily cross the blood-brain barrier, reaching the central nervous system, where they pass into the neuron through its membrane, being trapped in it and from there offer the image of the functional state of the same .
The most important indication of this test are the dementias and within them of prominent form the Alzheimer, dementia with a great social and sanitary impact in populations with high life expectancy. Other indications of this test are cerebrovascular accidents, brain death diagnosis, epilepsy and brain tumors. The use of quantitative methods has revolutionized this imaging technique and are increasingly being used. The objective is to enable the use of these techniques in the clinical routine, thus improving even more the diagnostic efficiency of these diseases. Qubiotech is developing a general purpose SPECT image quantification tool for the early diagnosis of neurodegenerative diseases. Expected launch in 2018
Kjell Erlandsson, Irène Buvat, P Hendrik Pretorius, Benjamin A Thomas and Brian F Hutton (2012). A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Physics in Medicine & Biology, Volume 57, Number 21